Neuberger Berman Group
RIGL icon

Neuberger Berman Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Neuberger Berman Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,200
Closed -$289K – 1688
2018
Q2 		$289K Buy
+10,200
New +$363K ﹤0.01% 1529
2014
Q3 		– Sell
-17,260
Closed -$627K – 1694
2014
Q2 		$627K Sell
17,260
-240
-1% -$8.16K ﹤0.01% 1345
2014
Q1 		$679K Buy
+17,500
New +$624K ﹤0.01% 1281

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Neuberger Berman Group's RIGL Position: Q3 2018 in Review

Neuberger Berman Group sold out of Rigel Pharmaceuticals (RIGL) in Q3 2018, closing a stake of 10,200 shares — an estimated $289K sold.

Neuberger Berman Group first reported a position in RIGL in Q1 2014 and held it in 3 quarters. The position peaked at $679K in Q1 2014. 135 funds tracked by Wall St. Rank hold RIGL as of Q3 2018.

  • Neuberger Berman Group reported no remaining Rigel Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 10,200 Rigel Pharmaceuticals shares in Q3 2018, an estimated $289K.
  • Neuberger Berman Group first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Neuberger Berman Group's Rigel Pharmaceuticals position peaked at $679K in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2018.

Based on Neuberger Berman Group's 13F filing for Q3 2018, filed 13 Nov 2018.